Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis
NEW ORLEANS and LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing...